Compare Abeona Therapeutics Inc (ABEO) vs YieldMax AMD Option Income Strategy ETF (AMDY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs YieldMax AMD Option Income Strategy ETF — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while YieldMax AMD Option Income Strategy ETF trades at $52.65. Which is the better fit depends on your goals.
| ABEO | AMDY | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $7.23 | $59.52 |
52-Week Low | $4.17 | $29.80 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
AMDY trades at $56.10, up 5.35% in the last 24 hours, with technical indicators showing a bullish trend. The stock exhibits strong weekly dividend distributions, but key valuation and profitability ratios are unavailable. Recent news highlights high-yield potential alongside concerns over net asset value erosion due to its option income strategy.
The outlook for AMDY is mixed; high dividend yields attract income investors, but structural risks from NAV erosion and dependency on AMD's stock performance pose significant challenges. Investors should weigh the income benefits against potential capital depreciation in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About YieldMax AMD Option Income Strategy ETF
AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.
Read more on AMDY →
